Skip to main content
SpringerLink
Log in

True Positive Somatostatin Receptor Scintigraphy in Primary Breast Cancer Correlates with Expression of sst2A and sst5

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

[111 In-DTPA-D-Phe1]-octreotide scintigraphy has been shown to reveal somatostatin receptor-positive lesions in the majority of primary breast cancers. We have recently developed a panel of somatostatin receptor subtype-specific antibodies that effectively stain formalin-fixed, paraffin-embedded breast cancer tissue. However, it is uncertain to what extend somatostatin receptors detected during immunohistochemical staining represent functional binding sites responsible for high tracer uptake during somatostatin receptor scintigraphy.

Patients and methods. we, therefore, conducted a prospective study in which 23 patients with suspected breast tumors were included. All patients received [111In]-pentetreotide scintigraphy. After surgical removal of the tumor, the somatostatin receptor status was determined by immunohistochemistry.

Results. Among 20 pathologically proven malignant tumors (14 ductal and six lobular carcinomas), 13 (∼65%) were scintigraphically visible. Of the 20 primary breast cancer specimens analyzed, three tumors (∼15%) were positive for sst1, nine (∼45%) revealed immunoreactive sst2A receptors, eight (∼40%) showed sst3-like immunoreactivity, and 14 (∼70%) were positive for sst5. There was an excellent correlation between the outcome of somatostatin receptor scintigraphy and expression of sst2A (P = 0.025) as well as sst5 (P < 0.001) but not expression of either sst1 (P = 0.343) or sst3 (P = 0.400).

Conclusion. Both sst2A and sst5 can be responsible for high tracer uptake during [111In]-pentetreotide scintigraphy in primary breast cancer. Thus, somatostatin receptor scintigraphy may possibly be of value in the detection of proven somatostatin receptor sst2A- and/or sst5-positive lesions in metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, Jeekel J, Reubi JC, Lamberts SW: Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343:640–643, 1994

    CAS  PubMed  Google Scholar 

  2. van Eijck CH, Kwekkeboom DJ, Krenning EP: Somatostatin receptors and breast cancer. Q J Nucl Med 42: 18–25, 1998

    CAS  PubMed  Google Scholar 

  3. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S: Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80: 2974–2979, 1995

    Article  CAS  PubMed  Google Scholar 

  4. Schaer JC, Waser B, Mengod G, Reubi JC: Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70: 530–537, 1997

    Article  CAS  PubMed  Google Scholar 

  5. Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN: Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 75: 798–803,1997

    CAS  PubMed  Google Scholar 

  6. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S, Munz DL: Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 39: 224–227, 1998

    CAS  PubMed  Google Scholar 

  7. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C, Höllt V: Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 4:2047–2052, 1998

    CAS  PubMed  Google Scholar 

  8. Schulz S, Schreff M, Schmidt H, Händel M, Przewlocki R, Höllt V: Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. EurJ Neurosci 10: 3700–3708, 1998

    CAS  Google Scholar 

  9. Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V: Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6: 1865–1874, 2000

    CAS  PubMed  Google Scholar 

  10. Schulz S, Händel M, Schreff M, Schmidt H, Höllt V: Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J Physiol Paris 94:259–264, 2000

    CAS  PubMed  Google Scholar 

  11. Stroh T, Jackson AC, Sarret P, Dal Farra C, Vincent JP, Kreienkamp HJ, Mazella J, Beaudet A: Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis.Endocrinology 141: 354–365, 2000

    Article  CAS  PubMed  Google Scholar 

  12. Alberini JL, Meunier B, Denzler B, Devillers A, Tass P, Dazord L, Le Simple T, Laissue J, de Jong R, Le Cloirec J, Reubi JC, Bourguet P: Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 61:21–32, 2000

    CAS  PubMed  Google Scholar 

  13. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C: The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur JNucl Med 25: 668–674, 1998

    CAS  Google Scholar 

  14. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G: Inhibition of growth of MX-l, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 82: 592–598, 1999

    CAS  PubMed  Google Scholar 

  15. Huang CM, Wu YT, Chen ST: Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol 7: 453–461, 2000

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Otto-von-Guericke-University, Magdeburg, Germany

    Solveig Schulz, Kornelia Franke & Wolfgang Weise

  2. Department of Pathology, Otto-von-Guericke-University, Magdeburg, Germany

    Johannes Schmitt

  3. Department of Nuclear Medicine, Otto-von-Guericke-University, Magdeburg, Germany

    Thekla Helmholz & Hans-Jüurgen Otto

Authors
  1. Solveig Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thekla Helmholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kornelia Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans-Jüurgen Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wolfgang Weise
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schulz, S., Helmholz, T., Schmitt, J. et al. True Positive Somatostatin Receptor Scintigraphy in Primary Breast Cancer Correlates with Expression of sst2A and sst5 . Breast Cancer Res Treat 72, 221–226 (2002). https://doi.org/10.1023/A:1014972520302

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1014972520302

Search

Navigation